Sasha Taluri

Sasha Taluri

Auto-generated profile, based on publicly available information

Sasha Taluri


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Pediatric Neurology
Verified
Journal Article
Closed access
STSasha Taluri
Sasha Taluri
APAlan K Percy
Alan K Percy
AAAmitha L. Ananth
Amitha L. Ananth

26 June 2026 in Human Genetics
Verified
Journal Article
Open access
EWElizabeth J. Wilk
Elizabeth J. Wilk
STSasha Taluri
Sasha Taluri
THTimothy C. Howton
Timothy C. Howton
ACAnthony B. Crumley
Anthony B. Crumley
MMMichal Mrug
Michal Mrug
BLBrittany Lasseigne
Brittany Lasseigne
While falling costs have expanded access to genomic sequencing, clinical utility is frequently hindered by the challenge of interpreting complex genetic data. Variant analysis for rare disease patients especially requires significant time and expertise, creating a bottleneck that delays diagnostics. Although advances in genetic variant classification have improved diagnostic precision, they have also increased the identification of variants of uncertain significance (VUSs), widening the interpretation gap between data generation and clinical actionability. The high prevalence of VUSs can lead to false reassurance or psychological distress by misinterpretting inconclusive results. We propose that artificial intelligence (AI) is a critical clinical decision-support tool for bridging this gap, offering a scalable framework to optimize variant interpretation and shorten the diagnostic odyssey. While reclassification ultimately requires biological evidence that AI cannot replace, these tools serve as essential aggregators and prioritizers, especially as guidelines transition toward the upcoming quantitative ACMG v4 framework. We advocate integrating AI throughout the genetic diagnostic workflow–from initial phenotyping to variant prioritization–to facilitate data-driven, personalized treatment. We outline current AI-assisted approaches and discuss anticipated challenges in this pursuit, such as privacy, training data bias and quality, model explainability, and the necessity of a total product life cycle for validation. To address these challenges, we provide recommendations for "human-in-the-loop" design and intuitive workflow integration to ensure AI tools meet the highest standards of precision, reproducibility, and transparency to maximize adoption. By standardizing AI across the variant analysis pipeline, we can fast-track the path to genetic diagnoses, effectively bridging the interpretation gap and enabling rapid delivery of personalized medical interventions.

21 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EJEmma Jones
Emma Jones
STSasha Taluri
Sasha Taluri
EWElizabeth Wilk
Elizabeth Wilk
BLBrittany Lasseigne
Brittany Lasseigne
Drug repurposing, identifying FDA-approved drugs for new indications, reduces the time and money required for a drug to reach the clinic and capitalizes on the increasing number of publicly available online data. Attrition rates for repurposing studies are lower than compared to drug discovery. Still, repurposing candidates often fail downstream despite their biological relevance, attributing to a lack of safety and/or efficacy. Current approaches may be limited in separating biological signals from technical noise and incorporating relevant clinical information to evaluate promising candidates in preclinical analyses. Many drug repurposing approaches have been developed; however, a gold standard has yet to be determined. In addition, repurposing analyses often yield many potential candidates that require further prioritization to ensure clinical viability. Thus, prioritization of the optimal candidates by incorporating more information from available resources is critical. Here, we reviewed prioritization criteria and developed a workflow implementing 1) drug-specific, 2) target-specific, and 3) disease-specific considerations to address challenges in current drug repurposing efforts. Our workflow streamlines drug candidate prioritization using a stepwise evaluation process and vetted resources for each consideration to guide researchers in better predicting the most robust candidates and facilitating the most promising ones for clinical adoption.

10 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EWElizabeth J. Wilk
Elizabeth J. Wilk
STSasha Taluri
Sasha Taluri
THTimothy C. Howton
Timothy C. Howton
ACAnthony B. Crumley
Anthony B. Crumley
MMMichal Mrug
Michal Mrug
BLBrittany Lasseigne
Brittany Lasseigne
While falling costs have expanded access to genomic sequencing, clinical utility is frequently hindered by the challenge of interpreting complex genetic data. Although advances in genetic variant classification have improved diagnostic precision, they have also increased the identification of variants of uncertain significance (VUSs), widening the interpretation gap between data generation and clinical actionability. The high prevalence of VUSs can lead to false reassurance or psychological distress, as patients and non-expert clinicians may misinterpret inconclusive results. We propose that artificial intelligence (AI) is a critical clinical decision-support tool for bridging this gap, offering a scalable framework to optimize variant interpretation and shorten the diagnostic odyssey. We advocate integrating AI throughout the genetic diagnostic workflow–from initial phenotyping to variant prioritization–to facilitate data-driven, personalized treatment. We outline current AI-assisted approaches and discuss anticipated challenges in this pursuit, such as privacy, training data bias and quality, model explainability, and the necessity of a total product life cycle for validation. To address these challenges, we provide recommendations to ensure AI tools meet the highest standards of precision, reproducibility, and transparency. By standardizing AI across the variant analysis pipeline, we can fast-track the path to genetic diagnoses, effectively bridging the interpretation gap and enabling rapid delivery of personalized medical interventions.

15 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JFJaclyn M. Freeman
Jaclyn M. Freeman
STSasha Taluri
Sasha Taluri
EWElizabeth J. Wilk
Elizabeth J. Wilk
THTimothy C. Howton
Timothy C. Howton
PCPhillip H. Chumley
Phillip H. Chumley
BLBrittany Lasseigne
Brittany Lasseigne
Autosomal dominant polycystic kidney disease (ADPKD) is a complex disorder characterized by the progressive development of renal cysts. Disease progression is linked to ADPKD-driven metabolic and mitochondrial reprogramming that exacerbates ADPKD pathophysiology by impairing central energetic pathways, including mitochondrial respiration and glucose, lipid, and amino acid metabolism. Caloric intake interventions can attenuate disease progression, but are difficult for patients to achieve and limited in application. Given the extensive alterations that impact ADPKD drug targets (i.e., mammalian target of rapamycin (mTOR) signaling pathway, peroxisome proliferator–activated receptor (PPAR) family, etc.) and drug metabolism (i.e., pharmacokinetics, cytochrome P450 (CYP450) family, etc.), improved understanding of the mechanisms driving metabolic and mitochondrial reprogramming may foster the identification of novel ADPKD severity-modifying drug targets and/or drugs. Such drugs could synergistically complement tolvaptan (the only U.S. Food and Drug Administration (FDA)-approved ADPKD therapeutic), or serve as alternatives, as tolvaptan is costly and associated with hepatotoxicity. Repurposing FDA-approved drugs could accelerate translation to clinical practice by leveraging prior work to improve the traditional drug development pipeline. To facilitate identification of repurposed drugs for ADPKD, we review ADPKD-driven metabolic and mitochondrial reprogramming from the perspective of drug target identification for repurposing ADPKD therapeutics.

26 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
EWElizabeth J. Wilk
Elizabeth J. Wilk
STSasha Taluri
Sasha Taluri
TSTabea Soelter
Tabea Soelter
BLBrittany Lasseigne
Brittany Lasseigne
Background: SETBP1 haploinsufficiency disorder ( SETBP1 -HD) is a neurodevelopmental condition characterized by developmental delay, speech apraxia, motor deficits, and autism spectrum disorder (ASD), caused by deficiency of the transcription factor (TF) SETBP1. Since current management is limited to symptomatic relief, we defined a robust consensus molecular signature for SETBP1 -HD and prioritized drugs that converge with SETBP1 regulatory targets. Methods: We performed a meta-analysis of three independent transcriptomic datasets derived from in vitro models of SETBP1 deficiency. Using Robust Rank Aggregation (RRA), we overcame transcriptomic heterogeneity to establish a SETBP1 -HD consensus signature. We integrated this signature with known and spatio-temporal-aware SETBP1 interactions to prioritize key regulatory and drug targets. Finally, we screened the LINCS L1000 drug perturbation database for compounds capable of reversing the consensus SETBP1 -HD gene signature. Results: Our regulatory analysis yielded potential, critical therapeutic windows, while our consensus analysis identified LIN28A (a key regulator of developmental timing) and SPON1 ( F-spondin) as novel, robustly upregulated targets across models. LIN28A provides a potential mechanism for the dysregulated neurogenesis and progenitor proliferation observed in patient-derived cells, while SPON1 links molecular dysfunction to motor and connectivity deficits seen in patients. Our in silico drug repurposing screens prioritized celecoxib and buspirone as top therapeutic candidates. Mechanistically, celecoxib targets the prioritized SETBP1 regulatory target COX-2 ( PTGS2 ) to mitigate neuroinflammation, while the potent neuromodulator buspirone chemically stabilizes vulnerable circuits to correct the underlying neurotransmitter imbalance driven by SETBP1 loss. Limitations: This study relies on in silico consensus modeling derived from cell culture and animal models. While robust statistical thresholds were applied, the therapeutic efficacy of the identified candidates on behavioral phenotypes—specifically motor deficits and speech apraxia—requires in vivo validation. Additionally, the specific contribution of LIN28A to the ASD phenotype warrants further functional characterization. Conclusions: We defined a unified molecular mechanism for SETBP1 -HD, in which dosage deficiency leads to a delayed neurogenic state driven by LIN28A , coupled with connectivity defects driven by SPON1, ultimately resulting in a destabilized excitation/inhibition balance. We identify celecoxib and buspirone as top therapeutic candidates, offering an immediate translational pathway to address the core neurodevelopmental, circuitry, and motor challenges associated with SETBP1- HD variants.